Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY011 in Advanced Pancreatic Cancer
NCT04966143Phase 1Unknown
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY011 in pancreatic cancer (PC), sponsored by Shanghai Longyao Biotechnology Co., Ltd. Primary endpoint: Overall Response Rate at 1 month. Status: unknown.
02
Drugs
LY011
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04966143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966143.